Published in Eur J Neurosci on December 04, 2007
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J (2008) 1.43
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci (2011) 1.35
Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun (2008) 1.31
The role of DYRK1A in neurodegenerative diseases. FEBS J (2010) 1.23
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem (2010) 1.16
WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis (2011) 1.09
Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem (2009) 1.08
Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem (2009) 1.03
Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett (2009) 1.02
Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease. PLoS One (2011) 0.98
An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition. J Biol Chem (2012) 0.96
The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci (2014) 0.95
Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One (2012) 0.91
The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation. PLoS One (2011) 0.91
Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level. Mol Neurodegener (2012) 0.90
Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem (2009) 0.90
Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci (2014) 0.89
GSK-3beta phosphorylation of functionally distinct tau isoforms has differential, but mild effects. Mol Neurodegener (2009) 0.89
Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res (2011) 0.88
Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer's disease pathology. Int J Alzheimers Dis (2012) 0.88
Enhanced taupathy and AD-like pathology in aged primate brains decades after infantile exposure to lead (Pb). Neurotoxicology (2013) 0.87
Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer's disease. Oxid Med Cell Longev (2013) 0.87
Infantile postnatal exposure to lead (Pb) enhances tau expression in the cerebral cortex of aged mice: relevance to AD. Neurotoxicology (2014) 0.86
Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy. Int J Alzheimers Dis (2012) 0.84
Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. Sci Rep (2015) 0.84
Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer's disease. Alzheimers Res Ther (2014) 0.82
New age of neuroproteomics in Alzheimer's disease research. Cell Mol Neurobiol (2009) 0.81
Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target? Int J Alzheimers Dis (2012) 0.81
Effects of cell cycle inhibitors on tau phosphorylation in N2aTau3R cells. J Mol Neurosci (2008) 0.80
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
Pseudophosphorylation of tau protein directly modulates its aggregation kinetics. Biochim Biophys Acta (2010) 0.79
Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro. J Proteome Res (2013) 0.77
Human fetal tau protein isoform: possibilities for Alzheimer's disease treatment. Int J Biochem Cell Biol (2012) 0.76
Adenosine A2A receptor inactivation alleviates early-onset cognitive dysfunction after traumatic brain injury involving an inhibition of tau hyperphosphorylation. Transl Psychiatry (2017) 0.75
7,8-Dihydroxyflavone Ameliorates Cognitive Impairment by Inhibiting Expression of Tau Pathology in ApoE-Knockout Mice. Front Aging Neurosci (2016) 0.75
Genome-wide analysis of the WW domain-containing protein genes in silkworm and their expansion in eukaryotes. Mol Genet Genomics (2014) 0.75
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron (1993) 2.84
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta (2005) 2.46
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem (1993) 2.30
Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron (2002) 2.28
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm (Vienna) (2004) 1.78
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A (1997) 1.73
Granular tau oligomers as intermediates of tau filaments. Biochemistry (2007) 1.67
C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci (2000) 1.67
Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem (2002) 1.62
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem (2004) 1.58
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A (2007) 1.50
Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J Neurochem (1993) 1.43
Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett (2006) 1.35
Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett (1998) 1.33
Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci (2002) 1.31
Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci (2007) 1.31
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem (2001) 1.28
Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res (1992) 1.26
Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett (2002) 1.26
Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate. J Biol Chem (2002) 1.20
The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res (1993) 1.19
Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience (2002) 1.19
beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem (2003) 1.19
The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell (1999) 1.17
PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett (2006) 1.12
Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol (2007) 1.11
Differences in microtubule binding and self-association abilities of bovine brain tau isoforms. J Biol Chem (1993) 1.05
Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem (2004) 1.03
Subcellular distribution of protein phosphatases and abnormally phosphorylated tau in the temporal cortex from Alzheimer's disease and control brains. J Neural Transm (Vienna) (1998) 0.99
TMAO promotes fibrillization and microtubule assembly activity in the C-terminal repeat region of tau. Biochemistry (2006) 0.98
Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett (1996) 0.97
Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett (2006) 0.97
Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol (2006) 0.96
Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem (2002) 0.96
Hyperphosphorylation of tau and protein phosphatases in Alzheimer disease. Panminerva Med (2006) 0.92
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res (2009) 15.15
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61
The genome of the model beetle and pest Tribolium castaneum. Nature (2008) 6.50
Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature (2006) 6.28
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
A G protein-coupled receptor is a plasma membrane receptor for the plant hormone abscisic acid. Science (2007) 4.61
RNA-Seq analysis to capture the transcriptome landscape of a single cell. Nat Protoc (2010) 4.35
Limitations and potentials of current motif discovery algorithms. Nucleic Acids Res (2005) 4.28
Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. PLoS Comput Biol (2008) 3.02
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol (2007) 2.77
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 2.75
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Cerebrospinal fluid pressure in glaucoma: a prospective study. Ophthalmology (2009) 2.60
HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 2.59
Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta (2005) 2.46
Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci (2005) 2.35
Immune-driven recombination and loss of control after HIV superinfection. J Exp Med (2008) 2.34
Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol (2011) 2.33
SCLERAL AND CHOROIDAL THICKNESS IN SECONDARY HIGH AXIAL MYOPIA. Retina (2016) 2.28
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med (2010) 2.13
Serum γ-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart (2012) 2.10
The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat (2008) 1.97
Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol (2008) 1.94
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging (2008) 1.89
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc Natl Acad Sci U S A (2012) 1.75
Diaqua-1κO,2κO-(2,2'-bi-1H-imidazole-1κN,N)(oxalato-2κO,O)di-μ-oxido-κO:O-dioxido-1κO,2κO-dimolyb-denum(V) trihydrate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.74
Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Langenbecks Arch Surg (2011) 1.72
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A (2008) 1.65
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem (2005) 1.64
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol (2011) 1.63
Fast protein tertiary structure retrieval based on global surface shape similarity. Proteins (2008) 1.60
Cerebrospinal fluid pressure in ocular hypertension. Acta Ophthalmol (2011) 1.59
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem (2004) 1.58
Bis{tris-[3-(2-pyrid-yl)-1H-pyrazole]zinc(II)} dodeca-molybdosilicate hexa-hydrate. Acta Crystallogr Sect E Struct Rep Online (2010) 1.58
Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol (2008) 1.58
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett (2009) 1.53
Impact of lymphatic vessel invasion on survival in curative resected gastric cancer. J Gastrointest Surg (2011) 1.52
Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology (2012) 1.50
A role for orexin in central vestibular motor control. Neuron (2011) 1.48
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain (2009) 1.48
The yeast eukaryotic initiation factor 4G (eIF4G) HEAT domain interacts with eIF1 and eIF5 and is involved in stringent AUG selection. Mol Cell Biol (2003) 1.46
Mutations in TUBB8 and Human Oocyte Meiotic Arrest. N Engl J Med (2016) 1.46
Parkin mono-ubiquitinates Bcl-2 and regulates autophagy. J Biol Chem (2010) 1.45
Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology (2007) 1.44
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J (2008) 1.43
Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol (2010) 1.41
Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis (2013) 1.40
The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (2007) 1.40
The functional role of a conserved loop in EAL domain-based cyclic di-GMP-specific phosphodiesterase. J Bacteriol (2009) 1.39
Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol (2008) 1.39
Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener (2008) 1.38
A genome-wide inventory of neurohormone GPCRs in the red flour beetle Tribolium castaneum. Front Neuroendocrinol (2007) 1.38
Complete genome sequence of a novel porcine circovirus-like agent. J Virol (2012) 1.37
Notch1 regulates the growth of human colon cancers. Cancer (2010) 1.37
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol (2005) 1.37
Prevalence of porcine circovirus-like agent P1 in Jiangsu, China. Virol J (2011) 1.35
Primary malignant amelanotic melanoma of the female genital tract: report of two cases and review of literature. Melanoma Res (2009) 1.35
Reduction of false positives by internal features for polyp detection in CT-based virtual colonoscopy. Med Phys (2005) 1.34
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 1.33
Clinical features of solitary necrotic nodule of the liver. Hepatobiliary Pancreat Dis Int (2008) 1.32